Last reviewed · How we verify
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation.
Details
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 1 |
| Start date | Wed Feb 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jan 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Multiple Myeloma
Interventions
- Biospecimen Collection
- Bone Marrow Aspirate
- Bone Marrow Biopsy
- Computed Tomography
- Ixazomib Citrate
- Lenalidomide
- Placebo Administration
- Positron Emission Tomography
- Quality-of-Life Assessment
- Questionnaire Administration
Countries
Puerto Rico, United States